MedTrace Logo

A Study of JNJ-64281802 for the Prevention of Dengue Infection

NCT05201794 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1595

Last updated 2025-07-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the prophylactic effect of JNJ-64281802 with respect to the prevention of laboratory-confirmed dengue virus (DENV) infection up to the last day of dosing among participants who have no evidence of current DENV infection at baseline.

Conditions

  • Dengue

Interventions

DRUG

JNJ-64281802

JNJ-64281802 tablets will be administered orally as per the defined regimens.

DRUG

Placebo

Matching placebo for each dose level as tablet will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-22
Primary Completion
2024-06-26
Completion
2024-06-26
FDA Drug
Yes

Countries

  • Brazil
  • Colombia
  • Malaysia
  • Mexico
  • Panama
  • Peru
  • Philippines
  • Puerto Rico
  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05201794 on ClinicalTrials.gov